BR0315178A - Eritropoietina: remodelagem e glicoconjugação de eritropoietina - Google Patents

Eritropoietina: remodelagem e glicoconjugação de eritropoietina

Info

Publication number
BR0315178A
BR0315178A BR0315178-6A BR0315178A BR0315178A BR 0315178 A BR0315178 A BR 0315178A BR 0315178 A BR0315178 A BR 0315178A BR 0315178 A BR0315178 A BR 0315178A
Authority
BR
Brazil
Prior art keywords
erythropoietin
remodeling
glycoconjugation
peptide
deleting
Prior art date
Application number
BR0315178-6A
Other languages
English (en)
Inventor
Shawn Defrees
David Zopf
Robert Bayer
David Hakes
Caryn Bowe
Xi Chen
Original Assignee
Neose Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/032263 external-priority patent/WO2003031464A2/en
Priority claimed from US10/410,945 external-priority patent/US7214660B2/en
Application filed by Neose Technologies Inc filed Critical Neose Technologies Inc
Publication of BR0315178A publication Critical patent/BR0315178A/pt

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"ERITROPOIETINA: REMODELAGEM E GLICOCONJUGAçãO DE ERITROPOIETINA". A invenção inclui métodos e composições para a remodelagem uma molécula de peptídeo, que inclui a adição ou deleção de um ou mais grupos glicosil a um peptídeo, e/ou a adição de um grupo de modificação ao peptídeo.
BR0315178-6A 2002-10-09 2003-10-08 Eritropoietina: remodelagem e glicoconjugação de eritropoietina BR0315178A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/US2002/032263 WO2003031464A2 (en) 2001-10-10 2002-10-09 Remodeling and glycoconjugation of peptides
US10/287,994 US7138371B2 (en) 2001-10-10 2002-11-05 Remodeling and glycoconjugation of peptides
US36077003A 2003-01-06 2003-01-06
US36077903A 2003-02-19 2003-02-19
US10/410,945 US7214660B2 (en) 2001-10-10 2003-04-09 Erythropoietin: remodeling and glycoconjugation of erythropoietin
PCT/US2003/031974 WO2004033651A2 (en) 2002-10-09 2003-10-08 Erythropoietin: remodeling and glycoconjugation of erythropoietin

Publications (1)

Publication Number Publication Date
BR0315178A true BR0315178A (pt) 2005-08-16

Family

ID=34841934

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315178-6A BR0315178A (pt) 2002-10-09 2003-10-08 Eritropoietina: remodelagem e glicoconjugação de eritropoietina

Country Status (2)

Country Link
BR (1) BR0315178A (pt)
NZ (1) NZ539415A (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
NZ542586A (en) 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
DK2257311T3 (da) 2008-02-27 2014-06-30 Novo Nordisk As Konjugerede Faktor VIII-Molekyler

Also Published As

Publication number Publication date
NZ539415A (en) 2008-12-24

Similar Documents

Publication Publication Date Title
BR0213207A (pt) remodelagem e glicoconjugação de peptìdeos
MXPA05003730A (es) Eritropoyetina: remodelado y glicoconjugacion de eritropoyetina.
WO2004099231A3 (en) Glycopegylation methods and proteins/peptides produced by the methods
BR0108713A (pt) Expressão hìbrida de proteìnas de neisseria
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
BRPI0311516A8 (pt) Composição de xampu de condicionamento e seu método de preparo
DK2207786T3 (da) 2´-Fluor-2´-deoxytetrahydrouridiner som cytidindeaminasehæmmere
BR0315275A (pt) Anticorpos que se ligam a receptor de eritropoietina
BR0317822A (pt) Composição fluoroquìmica
BR9910089A (pt) Composições e antìgenos de neisseria meningitidis
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
BRPI0601896A (pt) composições que contêm microgéis e agentes espessantes
CY1109465T1 (el) Νεες φαρμακευτικες φαρμακοτεχνικες μορφες μονταφινιλης
BR0003072A (pt) Fechadura de cilindro dotada de meios de orientação magneticamente operados
DK1383919T3 (da) Fremgangsmåder og sammensætninger til anvendelse af MHC klasse II-invariant kædepolypeptid som en receptor for makrofag migrationsinhiberede faktor
ATE468317T1 (de) Herstellung von 1,3-diphenylprop-2-en-1- onderivaten
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
CY1114532T1 (el) (2r)-2-[(4-σουλφονυλ)αμινοφαινυλ]προπαναμιδια και φαρμακευτικες συνθεσεις περιεχοντας τα
BR9909805A (pt) Certos inibidores de tiol de enzima de conversão de endotelina
PT1282418E (pt) Utilizacao de derivados pirazolo para o tratamento da infertilidade
TR200002955T2 (tr) Antitümör aktivitesi olan spisülozin bileşimleri
BRPI0415450A (pt) composições de antibióticos
BRPI0414299A (pt) composições farmacêuticas de liberação modificada de modafinil
BR0303912A (pt) Composição para o condicionamento, composição para o condicionamento durável, método para o condicionamento, método para o condicionamento durável, método para o cuidado ou tratamento e kit para o cuidado, tratamento, condicionamento ou condicionamento durável
BRPI0405791A (pt) Preparados de metal nobre e preparados de lustrina para a serigrafia direta e indireta

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BIOGENERIX AG (DE)

Free format text: TRANSFERIDO DE: NEOSE TECHNOLOGIES, INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: BIOGENERIX AG (DE)

B25D Requested change of name of applicant approved

Owner name: BIOGENERIX GMBH (DE)

B25A Requested transfer of rights approved

Owner name: RATIOPHARM GMBH (DE)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2483 DE 07-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.